Search Results
Feb 04, 2026, 16:01 ET ALLEGIANT TRAVEL COMPANY FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS
same rate as common stock. The basic and diluted earnings per share calculations for the periods presented reflect the two-class method mandated by ASC Topic 260, "Earnings Per Share." The two-class method adjusts both the net income and the shares used in the calculation. Application of the two-class
More news about: Allegiant Travel Company
Feb 04, 2026, 10:56 ET Knee Replacement Market Forecast 2031: Steady Growth at 4.38% CAGR Supported by Technological Advancements, Says a 2026 Mordor Intelligence Report
Instrumentation (PSI)Computer-NavigatedBy End UserHospitalsAmbulatory Surgical Centres (ASC)Orthopaedic Specialty ClinicsBy GeographyNorth AmericaEuropeAsia-PacificMiddle
More news about: Mordor Intelligence Private Limited
Feb 04, 2026, 10:00 ET Dr. Nathaniel Nataneli Joins OCLI Vision as Cornea Specialist
provides a comprehensive set of business support functions, including billing and collections, credential services, marketing, physician recruitment, ASC development, financial and accounting services, benefits and payroll management, and information technology. The company's corporate service center is
More news about: OCLI Vision
Feb 03, 2026, 10:30 ET Interventional Cardiology Devices Market worth $42.39 billion by 2031 | MarketsandMarkets™
outpatient procedures in developed countries, increasing patient willingness to choose the most convenient care settings, and rising investments in ASC infrastructure and capabilities are all accelerating the global adoption of interventional cardiology devices in ambulatory surgical centers.Inquire
More news about: MarketsandMarkets
Feb 03, 2026, 09:05 ET Nation's First Cardiac Arrhythmia-Focused Healthcare Network Launches with New Mexico's First ASC-Based Ablation Procedures
complete interventional cardiology services, creating a sustainable model for delivering advanced cardiac care in communities of all sizes.The ASC-based approach represents a fundamental shift in how advanced cardiac procedures can be delivered. Historically, cardiac ablation has been confined to
More news about: Current Clinic Management LLC
Feb 03, 2026, 09:05 ET La primera red de atención médica centrada en la arritmia cardíaca de la nación se lanza con los primeros procedimientos de ablación basados en ASC de Nuevo México
intervencionista, creando un modelo sostenible para brindar atención cardíaca avanzada en comunidades de todos los tamaños.El enfoque basado en ASC representa un cambio fundamental en la forma en que se pueden realizar los procedimientos cardíacos avanzados. Históricamente, la ablación cardíaca se
More news about: Current Clinic Management LLC
Feb 03, 2026, 08:00 ET CMS Maintains NOPAIN Act Eligibility for ON‑Q* and AmbIT* Infusion Pumps; Adds Game Ready* in 2026
Procedure Coding System (HCPCS) code eligible for separate payment in the HOPD and ASC settings. Game Ready GRPro 2.1 has also been assigned a unique, brand-specific HCPCS code (C9817) eligible for separate payment in the HOPD and ASC settings when medical necessity criteria and all other requirements are met.
More news about: Avanos Medical
Feb 02, 2026, 16:05 ET MGIC Investment Corporation Reports Fourth Quarter 2025 Results
these ordinary course disputes and legal proceedings will not have a material adverse effect on our financial condition or results of operations. Under ASC 450-20, until a loss associated with settlement discussions or legal proceedings becomes probable and can be reasonably estimated, we do not accrue an
More news about: MGIC Investment Corporation
Jan 29, 2026, 16:15 ET Ardmore Shipping Announces 2026 Investor Day in New York
HAMILTON, Bermuda, Jan. 29, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore" or the "Company") today announced that it will host its 2026 Investor Day on Thursday, February 12 at 12:00 P.M. Eastern Time in New York
More news about: Ardmore Shipping Corporation
Jan 29, 2026, 09:00 ET Advita Ortho Expands Navigation Platform with Next-Generation GPS Shoulder System
navigation system. Key system features5 include:Reusable active trackers that integrate into hospital and ASC workflows using existing instrumentation sterilization processes, helping reduce per-case costs compared to disposable tracker systemsCalibration
More news about: Advita Ortho, LLC
Jan 29, 2026, 08:00 ET Silicom Reports Q4 and Full Year 2025 Results
(*) Adjustments related to share-based compensation expenses according to ASC topic 718 (SFAS 123 (R))Logo:
More news about: Silicom Ltd.
Jan 29, 2026, 07:00 ET International Paper to Create Two Independent Public Companies and Reports Full-Year and Fourth Quarter 2025 Results
our business segments and assessing the performance of our business segments and is presented in our financial statement footnotes in accordance with ASC 280 - "Segment Reporting". Fourth quarter 2025 net sales by business segment and operating profit (loss) by business segment compared with the third
More news about: International Paper
Jan 29, 2026, 06:00 ET Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
China designed to evaluate the long-term safety of denifanstat (ASC40) in 240 patients with moderate to severe acne vulgaris. All the 240 patients, previously treated with denifanstat (ASC40) or placebo for 12 weeks, received denifanstat (ASC40) once daily for 40 weeks. The primary endpoints included: (1)
More news about: Ascletis Pharma Inc.
Jan 28, 2026, 16:28 ET SOUTHWEST AIRLINES REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS; EXPECTS STRONG 2026 FINANCIAL PERFORMANCE FROM BUSINESS TRANSFORMATION
an expiration date and thus will be able to be redeemed by Customers indefinitely. This change in policy was considered a contract modification under ASC 606, Revenue from Contracts with Customers, and the Company accounted for such change prospectively in third quarter 2022. At that time, based on historical
More news about: Southwest Airlines Co.
Jan 28, 2026, 16:05 ET Whirlpool Corporation Announces Fourth-Quarter and Full Year Results; Provides 2026 Guidance
our consolidated EBIT broken down by the Company's reportable segments and are metrics used by the chief operating decision maker in accordance with ASC 280. Consolidated EBIT also includes corporate "Other" of $45 million and $(504) million for the fourth quarters of 2025 and 2024, respectively.
More news about: Whirlpool Corporation
Jan 28, 2026, 09:44 ET Global Osteotomy Plates Market Projected to Reach USD 698.5 Million by 2035; Joint Preservation Technologies Overtaking Traditional Arthroplasty
5.1 %Shift to outpatient (ASC) orthopedic careCompetitive Landscape: The Battle for the Operating RoomThe market
More news about: Future Market Insights, Inc.
Jan 28, 2026, 08:43 ET COMPASS SURGICAL PARTNERS AND CARDIOVASCULAR INSTITUTE OF NORTHWEST FLORIDA BRING FIRST OUTPATIENT CATH LAB TO REGION
high-performing ambulatory surgery center (ASC) networks. For physician partners, Compass delivers proven pathways to ASC ownership, operational excellence, and long-term value. Health systems rely on Compass to scale surgical care efficiently — advancing ASC growth within core service areas and reaching
More news about: Compass Surgical Partners
Jan 27, 2026, 09:00 ET Palistar Capital Appoints Ginu Thomas to Expanded Leadership Role as Chief Operating Officer and Chief Financial Officer
www.palistar.com.Media ContactsMary Beth Grover / Keely Gispan ASC Advisors [email protected] /
More news about: Palistar Capital
Jan 25, 2026, 19:10 ET Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
tolerability of ASC30 titrated weekly was comparable to published results of orforglipron titrated every four weeks in the Phase III ATTAIN-1 study. The total treatment discontinuation rate due to adverse events for the ASC30 Phase II study for obesity or overweight was 4.8%.ASC30 was discovered
More news about: Ascletis Pharma Inc.
Jan 25, 2026, 19:10 ET 歌禮宣佈口服小分子GLP-1R激動劑ASC30治療糖尿病的13周美國II期研究完成首批受試者給藥
組與安慰劑組相比，空腹血糖相對基線的平均變化；至13周時，治療組與安慰劑組相比，體重相對基線的平均變化；以及安全性和耐受性。該II期研究將在美國多個中心入組約100例2型糖尿病的受試者。受試者將被按約2:3:3:2的比例，分別隨機分配至40毫克、60毫克和80毫克的ASC30片治療組及匹配的安慰劑組。ASC30將從1毫克開始，每週滴定（titrated weekly）至40毫克、60毫克和80毫克的目標劑量。關於歌禮制藥有限公司歌禮製藥有限公司是一家全價值鏈整合型生物技術公司，聚焦有望成為治療代謝疾病同類最佳（best-in-class）和同類首創（first-in-class）藥物的開發和商業化。利用公司專有的基於結構的AI輔助藥物發現（Artificial
More news about: 歌禮製藥有限公司
Jan 22, 2026, 09:08 ET Pixee Medical accelerates U.S. growth with appointment of Pierre Couture as Vice President of Marketing
leader."The Orthopedic market is evolving rapidly, creating a clear demand for an efficient guidance solution for total knee replacement, especially in the ASC setting. Pixee's augmented reality solution offers the perfect combination of efficiency, ease of use and accuracy. After seeing a demonstration of the
More news about: Pixee Medical
Jan 20, 2026, 16:30 ET Simmons First National Corporation Reports Fourth Quarter EPS of $0.54
(1) The Company has elected to use the CECL transition provision allowed for in the year of adopting ASC 326.
More news about: Simmons First National Corporation
Jan 20, 2026, 13:53 ET Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's Studies
IL-18, biomarkers that correlated strongly with motor improvementThese effects were observed and target engagement confirmed (reduced NLRP3, ASC, cleaved caspase-1, IL-1β, IL-18) in the brain in two models: a PD prevention model (i.e., α-synuclein pre-formed fibril model) and, critically,
More news about: Olatec Therapeutics, Inc.
Jan 20, 2026, 09:23 ET Yellow Wood Partners Portfolio Companies Suave Brands and Elida Beauty Complete Merger to Create Evermark, A Leading Global Platform of Personal Care Brands
www.yellowwoodpartners.com.ContactsYellow Wood Partners LLCASC AdvisorsSteve Bruce / Taylor Ingraham / Kylie Souder +1 (203) 992-1230
More news about: Evermark, LLC
Jan 20, 2026, 09:00 ET Tropical Cheese Names Ivonne Balsinde Chief Growth Officer
Frank, Wilkinson Brimmer Katcher212.355.4449AUA Media ContactMax RaydenSenior DirectorASC Advisors LLCTel: 203 992 1227Cell: 917 705 1970Email: [email protected]
More news about: Tropical Cheese